Need Help?
Copied to clipboard!

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (ADOPT PGx): Depression Trial

This study was comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depression Trial (this study). Participants could enroll in only one of the three trials. Trial-specific outcomes will be compared between participants in the intervention arm and control arms who have an actionable phenotype.

Depression: A prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria were randomly assigned to either immediate pharmacogenetic testing and genotype-guided anti-depressant therapy (Intervention arm) or standard care with 6-month delayed pharmacogenetic testing (Control arm). Actionable phenotypes are defined as CYP2C19 ultra-rapid metabolizers (UMs), rapid metabolizers (RMs) and poor metabolizers (PMs) or CYP2D6 ultra-rapid metabolizers (UMs) and poor metabolizers (PMs) for the depression trial.

This study includes approximately 1470 participants seen in primary care or psychiatry clinics who are already prescribed or anticipate to be prescribed an SSRI with existing CPIC guidelines.